Although introduction of the serum prostate-specific antigen (sPSA) test has helped to increase early detection and decrease mortality from prostate cancer, the test has limitations that have made its use in screening highly controversial [2,3,4,5,6,7]. Here, KLK3 is linked to prostate cancer.